Aytu BioPharma (NASDAQ:AYTU – Get Free Report) will likely be releasing its Q1 2027 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.2567) per share and revenue of $13.27 million for the quarter. Investors may visit the company’s upcoming Q1 2027 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:30 PM ET.
Aytu BioPharma Price Performance
AYTU stock opened at $1.79 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.13 and a quick ratio of 1.00. Aytu BioPharma has a 1 year low of $1.75 and a 1 year high of $3.06. The firm has a 50-day moving average of $2.05 and a 200 day moving average of $2.29.
Analyst Upgrades and Downgrades
AYTU has been the topic of a number of research analyst reports. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a report on Tuesday, September 22nd. Weiss Ratings lowered Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Finally, Zacks Research lowered Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $14.50.
View Our Latest Research Report on Aytu BioPharma
About Aytu BioPharma
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines and other healthcare products. The company’s portfolio has primarily centered on treatments for attention-deficit/hyperactivity disorder (ADHD), along with select pediatric and primary-care products.
Aytu’s ADHD products have included Adzenys XR-ODT, an extended-release orally disintegrating tablet containing amphetamine; Cotempla XR-ODT, an extended-release orally disintegrating tablet containing methylphenidate; and Evekeo, an amphetamine sulfate product.
Read More
- Five stocks we like better than Aytu BioPharma
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
